Core Insights - Xcelerate, Inc. has made significant strategic adjustments in 2025 to align resources with long-term objectives, including the sale of its interest in ESN Group to strengthen its financial position and refocus on core missions [2][3] Financial Developments - The sale of ESN Group was an all-cash transaction that allowed Xcelerate to eliminate merchant finance debt associated with ESN, thereby improving its balance sheet [2] - The proceeds from the ESN sale, along with funds raised in a private placement, position the company to implement its AI-assisted patient portal program in early 2026 [3] Strategic Initiatives - Xcelerate is renewing its focus on AfiyaSasa Africa, LLC, aiming to launch an AI-assisted patient portal in Tanzania, which will connect patients in remote areas to clinicians [3][4] - The company is advancing its medical device patents, including a Surgical Tool with Targeting Guidance, and has filed additional applications in the EU and China [4] Communication and Engagement - To enhance transparency and shareholder engagement, Xcelerate is updating its corporate website and increasing its social media presence to share insights and progress updates [5] - A dedicated Investor Relations email will be established to streamline communication with shareholders [5] Future Outlook - In 2026, Xcelerate plans to carefully advance its key initiatives, particularly the AfiyaSasa platform, with a focus on testing technology in clinical settings and refining operations [6] - The company aims to maintain regular updates and transparent communication with shareholders as it progresses with AI-driven healthcare solutions [6]

DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the ...

ANDOVER, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that it will ring the Nasdaq Stock Market Opening Bell on December 22, 2025. The event will take place at the Nasdaq MarketSite in New York’s Times Square and will feature CEO Byrna Ganz and members of the Company’s leadership team ...

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Palamina Corp. (TSXV: PA) (OTCQB: PLMNF) has acquired 100% of the mineral rights to the Esperanza concession covering a 60.75 hectare area located in the Santa Lucia district in southeastern Peru. Esperanza lies adjacent to Aftermath Silver Ltd.'s (TSXV: AMM) Berenguela silver copper manganese project which is hosted within a surface area of approximately 50 hectares. Berenguela hosts a current mineral resource estimate of 122.5 million ounces of sil ...

Group 1 - The AI-led tech sector is projected to achieve a third consecutive year of over 20% gains, raising questions among investors about future performance [1] - December's mixed performance for tech may indicate early signs of a shift in market dynamics [1] - Seeking Alpha's quantitative stock rating system and analytical tools are designed to provide insights and save time for investors [1] Group 2 - The founder of CressCap Investment Research, which was acquired by Seeking Alpha in 2018, has extensive experience in equity research and quantitative strategies [1] - The systematic stock recommendation tool, Alpha Picks, aims to assist long-term investors in building a high-quality portfolio [1] - The focus on a data-driven approach helps to eliminate emotional biases in investment decisions [1]

A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support BUZZ BOMB™ will power Ashley's elite training, recovery, and lifestyle needs with its best-in-class product In partnering with Aspire's BUZZ BOMBâ"¢ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand's industry-leading commitment to innovation ESTERO, FL / ACCESS Newswire / December 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ( ...

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced a public offering priced at $10 million, aimed at funding its development programs and general corporate purposes [2][3]. Offering Details - The offering consists of 157,000 ADS Units, each comprising one American depositary share (representing 100,000 ordinary shares) and two Series L warrants [2]. - Additionally, there are 2,891,781 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants [2]. - The public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit is priced at $3.2799 [2]. Financial Proceeds - The expected gross proceeds from the offering, before deducting fees and expenses, are approximately $10 million [3]. - The net proceeds will be utilized for development programs, working capital, and other corporate purposes [3]. Closing and Agent Information - The offering is anticipated to close on December 19, 2025, pending customary closing conditions [4]. - Maxim Group LLC is acting as the sole placement agent for this offering [4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7]. Product Details - eRapa is an oral formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and tumorigenesis [8]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes [9]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier [10][11].

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail. However, the initiative is capital intensive. Worse yet, the trajectory is driven by probability rather than linear growth.In other words, years of research and billions in investments can hinge on a single clinical readout or regu ...

Core Insights - GrocerIQ Holdings, Inc. has launched an autonomous restaurant supply platform that has generated strong early market interest, with over 50 restaurants joining the Early-Access Program waitlist within 24 hours of its launch [1] Industry Trends - There is a growing demand among restaurant operators for technology-driven alternatives to traditional food distribution methods, manual inventory planning, and reactive purchasing models, which are currently pressuring margins across the industry [1]

Core Insights - Aprea Therapeutics has made significant progress in its clinical programs and is optimistic about its growth potential in 2026 [2][10] Group 1: Clinical Programs - The lead program, APR-1051, a next-generation WEE1 inhibitor, is showing promising anti-tumor activity in the ongoing ACESOT-1051 dose-escalation study, with a notable 15% reduction in tumor burden observed [3][4] - The treatment has been well tolerated with no dose-limiting toxicities reported, and disease stabilization has been noted in several patients, with the longest duration of treatment reaching 222 days [3][4] - The company is expanding its clinical focus on HPV-positive patients due to early positive responses, aligning with preclinical data from MD Anderson Cancer Center [5] - Upcoming catalysts for APR-1051 include further safety and efficacy data expected in Q1 2026 and completion of dose escalation in 2026 [6] Group 2: ATR Inhibitor Program - The ATRN-119 program has reached its recommended Phase 2 dose for once-daily dosing, with a strategic shift towards evaluating combination therapies [7] - Enrollment in monotherapy dosing arms of the ABOYA-119 study is paused to conserve cash amid challenging fundraising conditions [7] - Future strategies may include combination therapies with DNA-damaging agents, supported by preclinical data indicating enhanced anti-tumor immune responses [8][9] Group 3: Financial Position - Aprea has completed a $3.1 million gross private placement financing, extending its cash runway into Q1 2027 [10][11] - The company emphasizes financial discipline and aims to enhance investor relations to better communicate its value proposition [11][12] Group 4: Company Overview - Aprea is focused on developing innovative cancer treatments that target cancer cell vulnerabilities while minimizing damage to healthy cells [14] - The company's lead programs, APR-1051 and ATRN-119, are both in clinical development for solid tumor indications [15]